To the full analysis
Buyback calculator for Telix Pharmaceuticals
Telix Pharmaceuticals stock: key metrics
TLXTelix Pharmaceuticals had an operating margin of 2.2% and a return on invested capital (ROIC) of 2.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 1999 | no data | no data | no data |
| 2000 | no data | no data | no data |
| 2015 | no data | no data | no data |
| 2016 | no data | no data | no data |
| 2017 | no data | no data | no data |
| 2018 | 100.0% | −14,167.6% | −7,087.1% |
| 2019 | 27.0% | −1,145.8% | −799.6% |
| 2020 | 61.2% | −847.7% | −861.1% |
| 2021 | 66.5% | −1,069.6% | −1,059.9% |
| 2022 | 59.3% | −57.4% | −65.0% |
| 2023 | 62.6% | 3.2% | 1.0% |
| 2024 | 65.1% | 10.5% | 6.4% |
| 2025 | 53.1% | 2.2% | −0.9% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 1999 | 0.0% | no data | 0.0% |
| 2000 | −5.5% | −13.0% | −5.3% |
| 2015 | 0.0% | no data | 0.0% |
| 2016 | 0.0% | no data | 0.0% |
| 2017 | −12.9% | −9.0% | −12.5% |
| 2018 | −26.1% | −36.5% | −18.0% |
| 2019 | −39.8% | −38.9% | −27.2% |
| 2020 | −56.8% | −30.3% | −28.4% |
| 2021 | −100.0% | −61.1% | −73.3% |
| 2022 | −100.0% | −60.0% | −40.8% |
| 2023 | 3.5% | 7.7% | 1.3% |
| 2024 | 8.8% | 30.3% | 3.3% |
| 2025 | −1.7% | 2.3% | −0.6% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 14 Nov 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.